Last update Feb. 12, 2020
Very Low Risk
A synthetic deoxyribonuclease obtained by human recombinant technology (rhDNase). A protein structure formed by 260 amino acids. It behaves like an enzyme that hydrolyzes DNA in mucus. Indicated as a mucolytic in patients with cystic fibrosis.
Administration via inhalation once to twice a day.
Since the last update we have not found published data on its excretion in breastmilk.
Systemic absorption is very low and there is no accumulation. DNase is normally present in human serum. Endogenous plasma levels of DNase were not significantly modified after inhalation treatment over several months (FDA 2018, AEMPS 2015).
Its very high molecular weight makes it very unlikely it will transfer into breastmilk in significant amounts (AEMPS 2015).
Due to its protein nature, it is inactivated in the gastrointestinal tract, not being absorbed (practically zero oral bioavailability), which hinders transfer to infant plasma from breastmilk.
We do not have alternatives for Dornase Alfa since it is relatively safe.
Suggestions made at e-lactancia are done by APILAM team, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.